Literature DB >> 25115715

[Screening of malnutrition risk versus indicators of nutritional status and systemic inflammatory response in newly diagnosed lung cancer patients].

P Illa, M Tomíšková, J Skřičková.   

Abstract

BACKGROUND: Most lung cancers are already advanced at the time of dia-gnosis. In these patients, a frequent symptom is protein energy malnutrition, often diagnosed prior to oncological treatment. Malnutrition results in poor tolerance of treatment and increased morbidity and mortality.
METHODS: Nutritional Risk Screening (NRS) 2002 adapted for oncological patients was used to assess the risk of undernutrition in a group of 188 lung cancer patients. The risk was evaluated on a 6- point scale according to common signs of nutritional status and tumor and its treatment risk factors. A score of 3 and more (called "nutritional risk") means a significant risk of malnutrition. Furthermore, pretreatment nutritional characteristics were evaluated in patients (including the value of BMI) and laboratory values indicating malnutrition/ acute phase response (albumin/ C reactive protein - CRP).
RESULTS: Acceptable NRS score was found in 50.6%, while in 45.3% was suggested into risk of malnutrition ("nutritional risk"). Only 6.6% of our patients had a BMI less than 20 kg/ m2. Significant differences in albumin and CRP values in various categories of NRS were confirmed.
CONCLUSION: Initial signs of cancer malnutrition may be overlooked in patients who fall within or above the range of BMI for adequate weight, although these patients may be at significant risk of malnutrition. The indicators of nutritional status and systemic inflammatory responses were significantly associated with resulting values NRS score.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25115715     DOI: 10.14735/amko2014261

Source DB:  PubMed          Journal:  Klin Onkol        ISSN: 0862-495X


  1 in total

1.  Prevalence of hospital malnutrition in cancer patients: a sub-analysis of the PREDyCES® study.

Authors:  Mercè Planas; Julia Álvarez-Hernández; Miguel León-Sanz; Sebastián Celaya-Pérez; Krysmarú Araujo; Abelardo García de Lorenzo
Journal:  Support Care Cancer       Date:  2015-06-23       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.